AI Article Synopsis
- Radiomics is a growing field that extracts imaging data to create models predicting clinical outcomes, especially for non-invasive diagnosis and treatment of diseases like hepatocellular carcinoma (HCC).
- This area is still developing, lacking standardized evaluation methods, but shows promise for creating effective biomarkers for diagnosis and treatment response.
- The aim of the study is to provide an overview of radiomics principles related to HCC and to discuss its current challenges and potential future advancements.
Article Abstract
Background: Radiomics is an emerging field that extracts high-throughput imaging data from different types of images to build models and predict clinical outcomes ina non-invasive manner. This field currently is in the initial growth phase and lacks standardized evaluation criteria but remains a very promising tool for the future todevelop suitable biomarkers for diagnosis, prognosis, and treatment response assessments. The analysis of hepatocellular carcinoma by radiomics will contribute toearly diagnosis and treatment of tumors and improve survival and cure rates.
Aim: Herein, we aimed to provide an up-to-date overview of the principles of radiomics specifically regarding hepatocellular carcinoma (HCC) and discuss the current challenges and future advancements of radiomics for HCC.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12029-020-00493-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The therapeutic role of naringenin nanoparticles on hepatocellular carcinoma.
BMC Pharmacol Toxicol
January 2025
Biochemistry Department, Faculty of Science, Tanta University, Tanta, Egypt.
Background: Naringenin, a flavonoid compound found in citrus fruits, possesses valuable anticancer properties. However, its potential application in cancer treatment is limited by poor bioavailability and pharmacokinetics at tumor sites. To address this, Naringenin nanoparticles (NARNPs) were prepared using the emulsion diffusion technique and their anticancer effects were investigated in HepG2 cells.
View Article and Find Full Text PDFCoexistence of adenomyomatosis in a left-sided gallbladder: a case report.
Int J Emerg Med
January 2025
Department of general surgry, Faculty of medicine, Misr university for science and technology, Giza, Egypt.
Introduction: The coexistence of gallbladder (LSG) and adenomyomatosis (ADM) is extremely uncommon presenting a novel clinical dilemma that has not been previously documented. LSG refers to a anomaly where the gallbladder is situated to the left of the round ligament deviating from its usual position. This anomaly is rare, with reported occurrences ranging between 0.
View Article and Find Full Text PDFPNMA1 is a novel immune modulator and therapeutic target in hepatocellular carcinoma linked to bile acid metabolism.
Sci Rep
January 2025
Department of Breast Surgery, China-Japan Union Hospital of Jilin University, Changchun, 130033, China.
Hepatocellular carcinoma (HCC) necessitates innovative prognostic biomarkers and therapeutic targets. By investigating PNMA1 in HCC via the TCGA and GEO databases and our clinical data, we found that its overexpression is associated with worse survival. The relevance of PNMA1 extends to immune factors such as M1 macrophages, CD8 T cells, and immune checkpoints.
View Article and Find Full Text PDFAdvances in imaging techniques have evolved, allowing for early noninvasive diagnosis and improved management of high-risk patients with hepatocellular carcinoma (HCC). The hallmark imaging features of HCC on multiphasic cross-sectional imaging can be explained by the multistep process of hepatocarcinogenesis and is seen in 60% of cases. However, approximately 40% of cases do not abide by the classic imaging appearance and may pose a diagnostic challenge for radiologists.
View Article and Find Full Text PDFDonafenib activates the p53 signaling pathway in hepatocellular carcinoma, induces ferroptosis, and enhances cell apoptosis.
Clin Exp Med
January 2025
Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Donafenib is an improved version of sorafenib in which deuterium is substituted into the drug's chemical structure, enhancing its stability and antitumor activity. Donafenib exhibits enhanced antitumor activity and better tolerance than sorafenib in preclinical and clinical studies. However, the specific mechanism of its effect on hepatocellular carcinoma has not been reported.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!